- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06068855
Une étude pour évaluer l'efficacité des injections de BOTOX (toxine botulique de type A) pour le changement de la proéminence musculaire masséter chez les participants adultes (MMP EU P3)
BOTOX® (toxine botulique de type A) pour la réduction de la proéminence musculaire masséter : une étude de phase 3, multicentrique, randomisée, en double aveugle, contrôlée par placebo
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a narrower and more ovoid lower face shape. Treatments are available for masseter muscle prominice (MMP), but researchers are looking for new non-surgical treatments. This study will assess adverse events and effectiveness of BOTOX in adult participants with MMP.
BOTOX is being investigated for the treatment of MMP. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is 1 in 4 chance that participants will be assigned to placebo. Around 248 adult participants with MMP will be enrolled in the study at approximately 30 sites in Europe.
Participants will receive either BOTOX or Placebo administered as 6 intramuscular injections to the masseter on Day 1. Participants who are eligible for retreatment will be given BOTOX on Day 180 and will be followed for up to 6 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Hamburg, Allemagne, 20146
- Universitaet Hamburg /ID# 247503
-
-
Bavaria
-
Munich, Bavaria, Allemagne, 80333
- Hautok and Hautok-cosmetics /ID# 246600
-
Munich, Bavaria, Allemagne, 80333
- Studienzentrum Theatiner46 /ID# 246601
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Allemagne, 50996
- Hautzentrum Koeln /ID# 247502
-
Düsseldorf, North Rhine-Westphalia, Allemagne, 40212
- Privatpraxis Dr. Hilton & Partner /ID# 246602
-
-
-
-
Antwerpen
-
Beerse, Antwerpen, Belgique, 2340
- Da Vinci Clinic /ID# 246731
-
Schilde, Antwerpen, Belgique, 2970
- Evolve Clinic /ID# 246729
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgique, 1090
- Universitair Ziekenhuis Brussel /ID# 246311
-
-
Oost-Vlaanderen
-
Melle, Oost-Vlaanderen, Belgique, 9090
- Lightfalls Clinic /ID# 247335
-
-
-
-
-
Plovdiv, Bulgarie, 4000
- Dermavist - Group Practice for Specialized Medical Care for Skin Disease /ID# 247630
-
Sofia, Bulgarie, 1700
- Medical Centre Dermatology Dr. Denkova EOOD /ID# 246591
-
Sofia, Bulgarie, 1407
- Medical Center Derma Vita EOOD /ID# 247327
-
-
-
-
-
Madrid, Espagne, 28006
- Grupo Pedro Jaen /ID# 246485
-
Madrid, Espagne, 28008
- Clinica Robega /ID# 252239
-
-
Pontevedra
-
Vigo, Pontevedra, Espagne, 36201
- Gavín Dermatólogos /ID# 252120
-
-
Valencia
-
Valencia, Valencia, Espagne, 46004
- Clinica Alejandria /ID# 247380
-
-
-
-
-
Antibes, France, 06160
- Mediti /Id# 246875
-
Cannes, France, 06400
- Cabinet Dermatologie et Esthetique /ID# 246871
-
Paris, France, 75007
- Cabinet médical /ID# 246873
-
Toulouse, France, 31000
- Cabinet de Chirurgie Plastique et Esthétique /ID# 246872
-
-
-
-
-
Latina, Italie, 04100
- Azienda Unita Sanitaria Locale Latina /ID# 246835
-
Roma, Italie, 00128
- Fondazione Policlinico Universitario Campus Bio-Medico /ID# 246836
-
Verona, Italie, 37134
- CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 246834
-
-
-
-
-
Edinburgh, Royaume-Uni, EH3 6RS
- Dr Nestor's Medical Cosmetic Centre /ID# 246437
-
London, Royaume-Uni, W1H 6AZ
- Interface Aesthetics Training Limited /ID# 248115
-
Sutton Coldfield, Royaume-Uni, B74 2UG
- MediZen /ID# 246431
-
-
North Lanarkshire
-
Coatbridge, North Lanarkshire, Royaume-Uni, ML5 3AP
- Waverley Medical Practice /ID# 246432
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Body mass index < 30 kg/m^2 using the calculation: BMI = weight (kg)/height (m)^2, rounded to the nearest whole number.
-
Participants meets the following criteria:
- Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right side of the face), as determined at screening and at the Day 1 visit by the investigator using the MMPS.
- Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right sides of the face), as determined at the Day 1 visit by the participant using the MMPS-P.
- MMP grades, as assessed by investigator and participant, do not need to be identical but have to be a minimum of Grade 4 with bilateral symmetry at Day 1.
-
Participants who responded "A lot" or "Extremely" bothered by the appearance of their MMP as measured by the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP) and attain a total score of ≥ 15 on the Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA), determined at the Day 1 visit.
Exclusion Criteria:
- Has current intraoral infection, including infection of the mouth or gums, or facial skin infection requiring medical treatment in the opinion of the investigator.
- Has weakness of the masseter, pterygoid, or temporalis muscles due to trauma, facial nerve injury, or other condition that could interfere with normal chewing and jaw clenching, as determined by the investigator.
- Excess lower facial fat, jowling, loose or lax skin in lower face, or parotid gland prominence that could interfere with MMPS or MMPS-P grading, as determined by the investigator.
- Has medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
- History of dental or surgical procedure for lower facial shaping or masseter muscle reduction.
- History of any soft tissue fillers in the jawline.
- Has prior exposure to botulinum toxin of any serotype to any part of the body (not including masseter muscle) within the 3 months prior to Day 1.
- History of or current TMJD, or presence of signs/symptoms of possible TMJD in the opinion of the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Double-Blind Period: Botox
Participants will receive 6 intramuscular injections of BOTOX to the masseter on Day 1. |
Intramuscular Injections
Autres noms:
|
|
Expérimental: Open-Label Period: Botox
Participants who are eligible for retreatment will be given open-label BOTOX on Day 180 and will be followed for up to 6 months |
Intramuscular Injections
Autres noms:
|
|
Comparateur placebo: Double Blind Period: Placebo
Participants will receive 6 intramuscular injections of Placebo to the masseter on Day 1. |
Intramuscular Injections |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale (MMPS) as assessed by the Investigator
Délai: Day 90
|
The investigator assessed the severity of the participant's MMP using the MMPS 5-point scale where: 1=minimal (best), 2=mild, 3=moderate, 4=marked, and 5=very marked (worst). |
Day 90
|
|
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale - Participant (MMPS-P) as assessed by the Participant
Délai: Day 90
|
The participant assessed the severity of their MMP using the MMPS-P 5-point scale where: 1=not at all pronounced (best), 2=mildly pronounced, 3=moderately pronounced, 4=pronounced, and 5=very pronounced (worst). |
Day 90
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Response of "Very Satisfied" or "Satisfied" on the Lower Facial Shape Questionnaire - Treatment Satisfaction Assessment (LFSQ-TXSAT)
Délai: Day 90 to Day 180
|
The LFSQ-TXSAT measures the participant's satisfaction with the effect of treatment on the appearance of their lower face where 2=Very satisfied, 1=Satisfied, 0=Neither satisfied nor dissatisfied, -1=Dissatisfied, -2=Very dissatisfied. |
Day 90 to Day 180
|
|
Response of "Not at all bothered" or "A little bothered" on the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP)
Délai: Day 90 to Day 180
|
The BIA-MMP is a single item evaluation of how bothered the participant is by the appearance of their lower face where 0=Not at all bothered, 1=A little bothered, 2=Somewhat bothered, 3=A lot bothered, 4=Extremely bothered. |
Day 90 to Day 180
|
|
Change from baseline in lower facial volume (cm^3)
Délai: Day 90
|
Lower facial volume is calculated from standardized images |
Day 90
|
|
Change from baseline in lower facial width (mm)
Délai: Day 90
|
Lower facial width is calculated from standardized images |
Day 90
|
|
Change from baseline in Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA) summary score
Délai: Day 90 to Day 180
|
The LFSQ-IA is a 6-item assessment that measures psychosocial impact of the appearance of the lower face where 0= Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit and 4=Extremely. |
Day 90 to Day 180
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- M23-123
- 2022-500568-37-00 (Autre identifiant: EU CT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Délai de partage IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Critères d'accès au partage IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .